If you’re still experiencing PsA symptoms
after a TNF blocker like HUMIRA® or ENBREL® ,

RINVOQ is

Different

and may help

RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL® ,

RINVOQ is

Different

and may help

RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

Tackle psoriatic arthritis symptoms with RINVOQ

Proven in clinical studies, RINVOQ can:

Significantly relieve joint pain, swelling, and stiffness for the majority of people in 3 months—for some, PsA symptoms improved in just 2 weeks

Leave skin* clear or almost clear for people with skin plaques

*RINVOQ is not approved to treat plaque psoriasis.

Stop further irreversible joint damage

Significantly reduce PsA fatigue


RINVOQ is a once-daily pill, not an injection.

A picture of the RINVOQ pill, which is a purple tablet with “a15” imprinted on it

Not actual size.

Select Important Safety Information

RINVOQ may cause serious side effects, including:

  • Serious Infections, Cancer and Immune System Problems, and Blood Clots.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.

Learn more about these and other serious side effects >

See full Important Safety Information below.

Quick Poll

Have you ever been prescribed a TNF blocker for psoriatic arthritis (PsA)?

Yes, l've been prescribed a TNF blocker

If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL®, RINVOQ, a JAK inhibitor, is different and may help.

What is RINVOQ? >

No, haven't

There are many PsA treatment options that work in different ways. If you haven’t seen improvement in your PsA symptoms, it may be time to discuss options with your rheumatologist.

PsA Treatment Options >

I'm not sure

There are many PsA treatment options that work in different ways. If you're not sure what type of medication you're currently taking, it's important to ask your rheumatologist. If you haven’t seen improvement in your PsA symptoms, it may be time to discuss options with your rheumatologist.

PsA Treatment Options >

Not yet diagnosed

If you believe you're experiencing PsA symptoms, it's important to see a rheumatologist to be evaluated. If you're diagnosed, you and your rheumatologist can work together to create a treatment plan that meets your personal needs.

Find a Rheumatologist >

HUMIRA® and ENBREL® are examples of TNF blockers.  ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

>95% of people with insurance are covered for RINVOQ

>95% of people with self- or employer-provided insurance plans or Medicare Part D are covered for RINVOQ.

The RINVOQ Complete Savings Card may help eligible commercially insured patients pay as little as $5 a month for RINVOQ.

Inspiring stories, real results

Hear how Tim takes on PsA with RINVOQ.

Hear how Tim takes on PsA with RINVOQ.

Stay in the know

Sign up for the latest tips, tools, and information to help you take PsA head on.

Share your RINVOQ story

Share your experience with RINVOQ to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.

Knowledge is power

Email or download the brochure to learn more about RINVOQ.

Please choose one

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

RINVOQ digital brochure

National commercial and Medicare Part D formulary coverage as of June 2023.

Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.